Amgen’s arthritis blockbuster Enbrel already owns an undesirable spot on the list of 10 drugs eligible for the first round of Medicare pricing negotiations. Now, the company is fighting back against a ...

A drugmaker whose product could be the first subjected to a price cap in Colorado is suing to throw out the state board that deemed its medication unaffordable. In February, the Colorado Prescription ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the United States. And unless a court rules otherwise, the Southern California ...

A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs deemed unaffordable in Colorado, finding that the maker of arthritis ...

US Food and Drug Administration staffers have concluded that Sandoz' biosimilar of Amgen's blockbuster Enbrel, dubbed GP2015, is "highly similar" to its reference product, pushing the drug closer to ...

WASHINGTON — Colorado is pioneering a new way for states to crack down on prescription drug costs. In a first-in-the-nation move, a state board voted to create a payment limit for a widely prescribed ...

An advisory panel for the Food and Drug Administration concluded Wednesday that Switzerland.-based Novartis AG’s version of Amgen’s arthritis drug Enbrel should be approved, according to Reuters. The ...

Generic drugmaker Sandoz (OTCQX:SDZXF) announced on Monday the filing of an antitrust lawsuit alleging that Amgen (NASDAQ:AMGN) used certain patent-related tactics to extend its U.S. market dominance ...

A Colorado board voted to move forward with setting a price ceiling on the arthritis drug Enbrel on Friday, a first-in-the-nation step that raises questions about whether a single state can reduce ...

Colorado could soon cap how much the state will pay for Amgen’s autoimmune drug Enbrel — in what would be the first such move from a state prescription drug affordability board. Affordability boards ...

Amgen Inc. on Tuesday reported fourth-quarter profits and sales that topped analysts’ expectations even as revenues dropped for one of its top sellers, the rheumatoid-arthritis drug Enbrel. The ...